- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06260709
En forskningsundersøgelse for at se på langsigtet behandling med en medicin kaldet NNC6019-0001 for mennesker, der har hjertesvigt på grund af transthyretin amyloidose
Open-label udvidelsesundersøgelse af langsigtet sikkerhed og effektivitet af NNC6019-0001 hos deltagere med transthyretin amyloid kardiomyopati (ATTR CM)
This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for approximately 6 years or until NNC6019-0001 is commercially or otherwise available to the participant, whichever comes first.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
- University of Calgary_Cardiology
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Ctr for Cardiovascular Innovation
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85054
- Mayo Clinic Arizona
-
-
California
-
Los Angeles, California, Forenede Stater, 90048
- Cedars-Sinai Medical Center_Los Angeles
-
Stanford, California, Forenede Stater, 94305
- Stanford Hlth Cre-Boswell Clin
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Mayo Clinic Jacksonville
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- NW Univ-Bluhm Cardiovasc Inst
-
Evanston, Illinois, Forenede Stater, 60208
- NW Univ-Bluhm Cardiovasc Inst
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- Univ of MD Schl of Med
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic Rochester
-
-
-
-
-
Créteil, Frankrig, 94000
- Ap-Hp-Hopital Henri Mondor
-
Toulouse, Frankrig, 31059
- Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil
-
Toulouse, Frankrig, 31059
- Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1
-
-
-
-
-
Groningen, Holland, 9713 GZ
- UMC Groningen
-
Utrecht, Holland, 3584 CX
- UMC Utrecht
-
Utrecht, Holland, 3584 CX
- Universitair Medisch Centrum Utrecht
-
-
-
-
PV
-
Pavia, PV, Italien, 27100
- Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo
-
-
Pi
-
Pisa, Pi, Italien, 56124
- Fondazione CNR-Regione Toscana Gabriele Monasterio
-
Pisa, Pi, Italien, 56124
- Fondazione Toscana Gabriele Monasterio - Dipartimento Cardiotoracico - UOC Cardiologia e Medicina Cardiovascolare
-
-
-
-
-
Fukuoka, Japan, 807-8556
- Hospital of the University of Occupational and Environmental Health, Cardiology, Nephrology
-
Hiroshima, Japan, 734-8551
- Hiroshima University hospital, Cardiovascular Medicine
-
Hiroshima, Japan, 734-8551
- Hiroshima University hospital_Cardiovascular Medicine
-
Kumamoto-shi, Kumamoto, Japan, 860-8556
- Kumamoto University Hospital, Cardiovascular Medicine
-
Nagano, Japan, 390-8621
- Shinshu University Hospital, Department of Neurology
-
Nagasaki, Japan, 852-8501
- Nagasaki University Hospital, Cardiovascular Medicine
-
Okayama, Japan, 700-8558
- Okayama University Hospital_Cardiovascular Medicine
-
-
-
-
-
Guimarães, Portugal, 4835-044
- Hospital da Senhora da Oliveira - Guimarães
-
Guimarães, Portugal, 4835-044
- ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães
-
Vila Real, Portugal, 5000-508
- ULS De Tras-Os-Montes E Alto Douro E.P.E. - Unidade Hospitalar de Vila Real
-
-
-
-
Madrid
-
Majadahonda, Madrid, Spanien, 28222
- Hospital Universitario Puerta de Hierro Majadahonda
-
-
-
-
-
Prague, Tjekkiet, 12808
- II. interni klinika VFN - Kardiologie a angiologie
-
-
-
-
-
Heidelberg, Tyskland, 69120
- Universitätsklinik Heidelberg Innere Medizin III Kardiologie, Angiologie, Pneumologie
-
Heidelberg, Tyskland, 69120
- UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie
-
München, Tyskland, 81377
- LMU Klinikum München Klinik und Poliklinik 1
-
Münster, Tyskland, 48149
- Uniklinik Münster, Klinik für Kardiologie I
-
Münster, Tyskland, 48149
- Universitätsklinikum Münster - Klinik für Kardiologie I
-
Würzburg, Tyskland, 97078
- Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz
-
Würzburg, Tyskland, 97078
- Universitatsklinikum Wurzburg AöR
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Completed study intervention in NN6019-4940 and attended the last study visit (week 64; visit 16), and no later than 12 weeks after visit 16.
- Expected to be on stable doses of cardiovascular medical therapy 6 weeks prior to the enrolment visit.
Exclusion Criteria:
- A prior solid organ transplant.
- Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, in-situ carcinomas of the cervix, or in-situ/high grade prostatic intraepithelial neoplasia (PIN) or low-grade prostate cancer) within 5 years before screening.
- Current treatment with calcium channel blockers with conduction system effects (e.g., verapamil, diltiazem). The use of dihydropyridine calcium channel blockers is allowed. The use of digoxin will only be allowed if required for management of atrial fibrillation with rapid ventricular response.
- Body weight greater than (>) 120 kilograms (kg) (264.6 pounds [lb]) at screening.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: NNC6019-0001
Participants will receive NNC6019-0001 intravenously every 4 weeks added to the standard of care up to 300 weeks. |
Intravenous NNC6019-0001 every 4 weeks added to the standard of care up to 300 weeks. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Treatment Emergent Adverse Events (TEAEs)
Tidsramme: From baseline (week 0) to up to 6 years
|
Measured as events. |
From baseline (week 0) to up to 6 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in 6-Minute Walk Test (6MWT)
Tidsramme: From baseline (week 0) to visit 28 (week 104)
|
Measured in meters. |
From baseline (week 0) to visit 28 (week 104)
|
|
Change in N-terminal-pro brain natriuretic peptide (NT-proBNP)
Tidsramme: From baseline (week 0) to visit 28 (week 104)
|
Measured in percentage. |
From baseline (week 0) to visit 28 (week 104)
|
|
Change in Myocardial Extracellular Volume (ECV)
Tidsramme: From baseline (week 0) to visit 28 (week 104)
|
Measured in percentage-points. |
From baseline (week 0) to visit 28 (week 104)
|
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
Tidsramme: From baseline (week 0) to visit 28 (week 104)
|
The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Measured in score on a scale. |
From baseline (week 0) to visit 28 (week 104)
|
|
Change in Troponin I
Tidsramme: From baseline (week 0) to visit 28 (week 104)
|
Measured in nanogram per milliliter (ng/mL). |
From baseline (week 0) to visit 28 (week 104)
|
|
Change in Global Longitudinal Strain (GLS) on Echocardiography
Tidsramme: From baseline (week 0) to visit 28 (week 104)
|
Measured in percentage-points. |
From baseline (week 0) to visit 28 (week 104)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- NN6019-7565
- 2022-502605-15-00 (Anden identifikator: European Medical Agency (EMA))
- U1111-1284-5820 (Anden identifikator: World Health Organization (WHO))
- jRCT2071240078 (Registry Identifier: JRCT)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .